Dimethylcurcumin (ASC-J9) is an androgen receptor degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion. Intraperitoneal injection of ASC-J9 into AR-polyQ transgenic SBMA (spinal and bulbar muscular atrophy) mice markedly improved disease symptoms, as seen by a reduction in muscular atrophy. ASC-J9 treatment ameliorated SBMA symptoms by decreasing AR-97Q aggregation and increasing VEGF164 expression with little change of serum testosterone. Moreover, mice treated with ASC-J9 retained normal sexual function and fertility[3]. Androgen receptor (AR) facilitated EAM (Experimental autoimmune myocarditis) development, and targeting AR with ASC-J9 attenuated cardiac injury and dysfunction by inhibiting macrophages polarization towards M1 macrophages[4]. Dimethylcurcumin (ASC-J9) (75 mg/kg, i.p.) degrades both fAR and AR3 in the xenografted tumors in vivo, and SC-J9-treated tumors has significantly decreased Ki67-positive cells[5].
搜索
